| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-207
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 |
| filingDate |
2016-03-07^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-02-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-02-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102363946-B1 |
| titleOfInvention |
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for the treatment of HCV |
| abstract |
A compound of structure (A), or a pharmaceutically acceptable salt or composition thereof, for the treatment of a host infected with or exposed to an HCV virus or other disorder described in more detail herein. |
| priorityDate |
2015-03-06^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |